KR20110017563A - Composition containing extracts of astragalus membranaceus - Google Patents

Abstract

PURPOSE: A composition containing Astraglus membranaceus extract is provided to prevent acne pigmentation and/or scar and to be used in cosmetic, food, or medial field. CONSTITUTION: A composition for suppressing acne pigmentation contains Astraglus membranaceus extract as an active ingredient. The Astraglus membranaceus extract suppresses gelatinase. The composition is used in the form of cosmetic product. A composition for aftercare of acne contains Astraglus membranaceus extract as an active ingredient. A food additive or health food contains Astraglus membranaceus extract.

Description

Composition containing Astragalus extract {Composition Containing Extracts of Astragalus membranaceus}

It relates to a composition containing Astragalus extract as an active ingredient.

Acne is usually caused by excess sebum associated with androgen secretion. Specifically, sebum is generated by the male hormones and hyperkeratinization of the pores is induced, and the pores are narrowed or blocked in severe cases. If the pores are narrowed or blocked, the sebum in the pores will not be discharged to the outside, forming a microsurface, and the proliferation of propionibacterium acnes, an anaerobic bacterium in the pores, may cause inflammation. have.

Induced inflammatory reactions may cause erythema, tingling, or swelling, and in severe cases, hyperpigmentation. In addition, squeezing or pressing the acne area increases the risk of leaving acne scars as the flares deteriorate and cause tissue damage.

Such acne inflammation may be caused by various causes, for example, various additives contained in cosmetics may cause acne inflammation while remaining on the skin. In addition, skin inflammation may also be caused by sebum, sweat or ultraviolet rays emitted from the body.

With respect to acne inflammation caused by various causes, research and development is focused only on the treatment of inflammation itself. However, even if the inflammation is treated, resulting in skin erythema or scars, etc., resulting in cosmetically bad results. Therefore, in the present invention, studies have been conducted to suppress or prevent pigmentation and scarring caused by acne inflammation.

An object of one embodiment of the present invention is to provide a composition for inhibiting acne pigmentation.

Another object of one embodiment of the present invention is to provide a composition for inhibiting acne scars.

Another object of an embodiment of the present invention is to provide a composition for aftercare for acne sequelae.

The composition according to an embodiment of the present invention is characterized by containing the Astragalus extract as an active ingredient.

The composition according to the embodiment of the present invention has an effect of suppressing acne pigmentation and / or scarring. Through this, it can be variously used in the field of cosmetics, food or medicine.

The composition according to the present invention contains the Astragalus extract as an active ingredient. Compositions containing the Astragalus extract are recognized for their effectiveness in preventing or inhibiting acne pigmentation and / or acne scars. In one embodiment, the composition according to the present invention is a composition for inhibiting acne pigmentation containing an extract of sulfur as an active ingredient. In another embodiment, the composition according to the present invention is a composition for inhibiting acne scars containing an extract of Astragalus as an active ingredient.

Astraglus membranaceus is a dicotyledonous plant that is a perennial plant of the Rosaceae legume. It grows mainly in the crevices of mountains and is 40 ~ 70 cm in height, and is distributed in Korea, Japan, northeastern China and eastern Siberia. In Chinese medicine, harvested in autumn to remove outcrops and fine roots and dried in the sun is called Astragalus.

Astragalus extract can be extracted by any of a variety of conventional methods without any limitation. In one embodiment, the Astragalus extract may be extracted with an organic solvent such as distilled water, C ₁ to C ₅ anhydrous or hydrous lower alcohol. In another embodiment, the Astragalus extract may be a hydrothermal extract. In the case of hot water extract, the extraction efficiency can be increased by setting both vacuum and high pressure conditions in the extraction process.

In one embodiment, the Astragalus extract is recognized to inhibit the gelatinase (gelatinase). Gelatinase is a type of proteolytic enzyme expressed in various types of molds and yeasts, and has a function of liquefying gelatin. The type of gelatinase is not particularly limited, and gelatinase genes expressed in humans include matrix metalloproteinase-9 (MMP-9) and matrix metalloproteinase-2 (MMP-2). In another embodiment, the Astragalus extract is recognized for its efficacy in inhibiting MMP-9 and / or MMP-2. The composition according to the invention prevents or inhibits acne scars by inhibiting gelatinases, specifically MMP-9 and / or MMP-2.

The composition according to the present invention can be utilized in various fields without particular limitation, and can be formulated, for example, in a topical skin preparation, and specifically in the form of a cosmetic or pharmaceutical composition.

The external preparation composition for skin according to the present invention may be formulated in the form of a dry powder which is in the form of a solution, a suspension or an emulsion in an oil or an aqueous medium, or dissolved in sterile, pyrogen-free water before use. Water-in-oil emulsions are oil-based vegetable oils such as olive oil or mineral oils such as liquid paraffin, derived from natural phospholipids such as soy lecithin and esters of anhydrous hecitol or fatty acids such as sorbitan monooleate, hydroxy The active ingredient is emulsified using compounds obtained by condensation of ethylene oxide with partial esters derived from anhydrous hexitol and fatty acids such as ethylene sorbitol monooleate as emulsifiers.

In one embodiment, in the composition for external application for skin according to the present invention, the content of the Astragalus extract may be 0.5 to 20% by weight based on the total weight of the composition. When the content of the extract is less than 0.5% by weight, the effect of managing and improving the skin condition is insignificant, and when the content of the extract is more than 20% by weight, the efficiency of the extract may be reduced and problems such as formulation stability may occur.

When the composition is formulated in the form of a cosmetic, it may be used for the purpose of preventing or improving acne pigmentation. It can also be used for the purpose of preventing or improving the occurrence of acne scars. The cosmetic formulation is not particularly limited, and may be, for example, a cosmetic composition having a formulation of a flexible longevity, nutrient longevity, massage cream, nourishing cream, pack, gel or skin adhesive cosmetic, and also lotion, ointment, gel Or transdermal dosage forms such as creams, patches or sprays. In addition, in each formulation, other components can be appropriately selected and blended by those skilled in the art without difficulty depending on the kind or purpose of use of other cosmetic compositions.

The present invention also provides a pharmaceutical composition comprising the composition. The pharmaceutical composition comprising the composition according to the present invention may be a composition for improving or inhibiting acne pigmentation and / or acne scars.

When the composition according to the present invention is applied to medicines, the composition may be formulated into an oral or parenteral dosage form in the form of solid, semi-solid or liquid by adding a commercially available inorganic or organic carrier.

Examples of the preparation for oral administration include tablets, pills, granules, soft and hard capsules, powders, fine granules, powders, emulsions, syrups, pellets, and the like. Can be mentioned. In addition, preparations for parenteral administration include injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like. In order to formulate the active ingredient of the present invention, it can be easily formulated according to the conventional method, and surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffers, suspending agents, and other commonly used auxiliaries can be suitably used.

The pharmaceutical composition according to the present invention may be administered orally, parenteral, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous.

In addition, the dosage of the active ingredient will vary depending on the age, sex and weight of the subject to be treated, the specific disease or pathology to be treated, the severity of the disease or pathology, the route of administration and the judgment of the prescriber. Dosage determination based on these factors is within the level of skill in the art. Typical dosages are from 0.001 mg / kg / day to 2000 mg / kg / day, more specifically from 0.5 mg / kg / day to 1500 mg / kg / day.

In one embodiment, the present invention provides a composition for aftercare containing Astragalus extract. More specifically, the present invention provides a composition for aftercare for comprehensively managing aftereffects such as pigmentation and / or scar due to skin trouble caused by acne and improving skin condition.

In another embodiment, in the aftercare composition according to the present invention, the content of the Astragalus extract may be 0.5 to 20% by weight based on the total weight of the composition. When the content of the extract is less than 0.5% by weight, the effect of managing and improving the skin condition is insignificant, and when the content of the extract is more than 20% by weight, the efficiency of the extract may be reduced and problems such as formulation stability may occur.

In the present invention, 'aftercare' refers to comprehensive aftercare for managing and improving skin condition. For example, if you enjoy playing in the beach, river or valley during the holiday season, or tanning or tanning for a long time, the skin is excessively exposed to ultraviolet rays may cause inflammation. In addition, various additives contained in sunscreen or oil applied to the skin may remain on the skin and may cause acne inflammation. In addition, skin problems such as acne inflammation can be caused by various causes in daily life. Aftercare is a generic term for skin care and post-care for skin condition improvement for skin problems including such acne inflammation. In addition, the composition for aftercare is meant to encompass compositions that adhere, deposit or apply to the skin for aftercare.

In one embodiment, the present invention provides a food additive, functional food or health food, etc. comprising the composition. Specifically, the composition may be a composition for improving or inhibiting acne pigmentation and / or scarring.

The composition according to the invention provides various types of food additives or functional foods comprising. It can be processed into fermented milk, cheese, yogurt, juice, probiotic and health supplement containing the composition, and can be used in the form of various other food additives.

In one embodiment, the composition may contain other ingredients and the like that can give a synergistic effect to the main effect within a range that does not impair the main effect of the present invention. For example, it may further include additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties. In addition, supplementary ingredients such as water soluble vitamins, oil soluble vitamins, polymer peptides, polymer polysaccharides and seaweed extract may be further included. The components may be appropriately selected and blended by those skilled in the art according to the formulation or purpose of use, and the amount of the additives may be selected within a range that does not impair the object and effect of the present invention.

The formulations of the compositions according to the invention may be in various forms, such as solutions, emulsions, viscous mixtures, tablets, powders, and the like, which may be administered by various methods such as simple drinking, injection, spray or squeeze.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited thereto.

[ Example  One] Hwanggi  Extract manufacturer

An eight-year-old astragalus was collected, washed, dried, and ground. A mixture of sulfur and water was extracted for 6-8 hours through a ceramic vacuum high pressure method at 80 ℃. The extract was centrifuged and filtered to remove impurities. Astragalus extract was prepared by adding 1,3-butylene glycol to the extract stock solution.

[ Experimental Example  1] cells ( Cell A) culture conditions

Hamster sebocytes were harvested from the sebaceous glands of 5 week old male golden hamster ears. For specific extraction methods, see Sato et al. (J Invest Dermatol 2001, 117: 965-70). The isolated sebaceous gland cells were cultured in a culture flask to make 2.35 × 10 ⁴ cells / cm ² .

Culture medium is fetal bovine serum (JH Bioscience, Tokyo, Japan) in DMEM / Ham's F12 medium; (1: 1) (DMEM / F12) (Invitrogen, Carlsbad, Calif.) 10% of L-glutamine (Invitrogen) and 10 nM of rhEGF (recombinant human epidermal growth factor; Progen Biotechnik GmbH, Heidelberg, Germany) were added.

As antibiotics, penicillin 100 mg / ml and streptomycin 100 mg / ml (all from GIBCO, Milan, Italy) were used together. Hamster sebaceous gland cells took 24 hours to fully adhere to the culture flask and were cultured at 37 ° C., 5% CO ₂ .

HaCaT, a human-derived keratinocyte cell line, adds 10% fetal bovine serum (JR Bioscience, Tokyo, Japan) to DMEM medium (Invitrogen, Carlsbad, CA), and penicillin 100 mg / ml, Streptomycin 100 mg / ml (all from GIBCO, Milan, Italy) was added to the culture medium, used at 37 ℃, 5% CO2 conditions.

Melan-a (melan-a), a melanocyte-derived melanocyte derived from C57BL / 6J mice, was treated with RPMI-1640 (Invitrogen, Carlsbad, Calif.) With fetal bovine serum (JRH Bioscience, Tokyo, Japan). % And 37%, 10% CO ₂ , using medium containing 200 nM tetradecanoyl phorbol acetate (TPA), 100 mg / ml penicillin, and 100 mg / ml streptomycin (all from GIBCO, Milan, Italy) The culture was used under conditions.

[ Experimental Example  2] Acne  Anti-inflammatory effect in in vitro  evaluation

In order to evaluate effectively the inhibitory effect of Astragalus extract, sebaceous gland cells and keratinocytes were used together to use an in vitro inflammation model with an environment similar to human acne lesions. The HaCaT keratinocytes and Golden Hamster sebaceous cells were each 6.0x10 ⁴ 3.75x10 ⁴ dogs each inoculated on a 24-well culture plate (well). After inoculation, the cells were allowed to adhere to the bottom of the culture plate for one day. In this case, fetal bovine serum (JH Bioscience, Tokyo, Japan) was added to DMEM / Ham's F12 medium ((1: 1) (DMEM / F12) (Invitrogen, Carlsbad, Calif.)). 10% was added and penicillin 100 mg / ml, streptomycin 100 mg / ml (all from GIBCO, Milan, Italy) were used.

50 µM linoleic acid, 50 µM arachidonic acid, 10 nM dihydrotestosterone, P. acnes 0.5% Was treated. At the same time, the extract was treated to observe the inhibitory effect of acne-induced inflammation. DMSO was used as a negative control, and 100 nM of isotretinoin, which is widely used as an acne treatment medicine, was used as a positive control. One day after treatment with the stimulant and extract, the granulocyte macrophage colony-stimulating factor (GM-CSF), IL-1 α (interleukin-1 alpha), a inflammatory cytokine dissolved in the culture medium, The concentrations of interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-α) were measured in 50 μl of medium by a multiplex bead-based cytokine assay.

More specifically, the following procedure was carried out: The solution in the 96-well filter plate, which had previously been wetted with the wash buffer, was aspirated off with a vacuum pump. Next, the cell culture was reacted with antibody-conjugated beads for 30 minutes. When the reaction was completed, the reaction antibody (detection antibody) was added for 30 minutes. Then, streptavidin-phycoerythrin (Streptavidin-PE; streptavidin-phycoerythrin) was placed in each well and waited for 30 minutes. After removing the non-stick Streptavidin-PE using the wash buffer, the amount of beads attached to the cytokine was analyzed using a Bio-plex 200 device.

The analysis results are shown in order in FIG. 1 (GM-CSF), FIG. 2 (IL-1 α), FIG. 3 (IL-8), and FIG. 4 (TNF-α). 1 to 4, it can be seen that the Astragalus extract according to the present invention inhibits inflammatory cytokines in a concentration-dependent manner. In particular, in Figure 1, it was confirmed that the Astragalus extract inhibits GM-SCF to a level similar to that of isotretinoin, a specialized drug.

[ Experimental Example  3] Acne  Sebum production inhibitory effect in in vitro  evaluation

In order to evaluate effectively the inhibitory effect of the extract of acne on sebaceous sebum production, sebaceous gland cells and keratinocytes were used together, and an in vitro model of an environment similar to human acne lesions was used. The HaCaT keratinocytes and Golden Hamster sebaceous cells were each 6.0x10 ⁴ 3.75x10 ⁴ dogs each inoculated on a 24-well culture plate (well). After inoculation, the cells were allowed to stick to the bottom of the culture plate for one day. In this case, fetal bovine serum (JH Bioscience, Tokyo, Japan) was added to DMEM / Ham's F12 medium ((1: 1) (DMEM / F12) (Invitrogen, Carlsbad, Calif.)). 10% was added and penicillin 100 mg / ml, streptomycin 100 mg / ml (all from GIBCO, Milan, Italy) were used.

50 μM of linoleic acid, 50 μM of arachidonic acid, 10 nM of dihydrotestosterone, 0.5% of P. acnes as a stimulant for acne-inflammation of cells after one day It was. At the same time, the extract was treated to observe the inhibitory effect of acne-induced inflammation. DMSO was used as a negative control, and 100 nM of isotretinoin, which is widely used as an acne treatment medicine, was used as a positive control. One day after treatment with the stimulant and extract, the amount of triglycerides produced in the cells was measured using Oil Red O staining.

More specifically, the following procedure was performed: Cells washed with PBS were fixed with 3.7% formaldehyde solution for 30 minutes. Fixed cells were washed three times with PBS and once with 70% ethanol and stained with 0.4% Oil Red O solution for 30 minutes. Stained cells were washed once with 70% ethanol and three times with PBS. Then, the Oil Red O solution stained with isopropanol was dissolved again and quantified by measuring the absorbance at 520 nm using a spectrophotometer.

Quantitative results are shown in FIG. 5. Referring to Figure 5, it can be seen that the Astragalus extract is effective for sebum inhibition. In particular, it exhibited an excellent sebum inhibiting effect at a concentration of 5 ppm or more.

[ Experimental Example  4] Acne  Pigmentation inhibitory effect in in vitro  evaluation

In order to evaluate effectively the inhibitory effect of the extract of the Astragalus extract, melanin-forming cells were used, and an in vitro model of the environment similar to the pigmentation induced by acne inflammation in humans was used. In a 24 well culture plate, 5.0 × 10 ⁴ melan-a melanin forming cells were seeded. After inoculation, the cells were allowed to stick to the bottom of the culture plate for one day. At this time, 10% of fetal bovine serum (JRH Bioscience, Tokyo, Japan) was added to RPMI-1640 (Invitrogen, Carlsbad, CA), TPA (tetradecanoyl phorbol acetate) 200 nM, penicillin (100 mg) / ml, streptomycin 100 mg / ml (all from GIBCO, Milan, Italy) was used to add.

50 μM of linoleic acid, 50 μM of arachidonic acid, 10nM of dihydrotestosterone, 0.5% of P. acnes as a stimulant for acne pigmentation on cells after one day And incubated for 5 days. Thereafter, the extract was treated to observe the effect of inhibiting acne pigmentation by the irritants. DMSO was used as a negative control and hydroquinone (1 μM) and kojic acid (200 ppm) were used as a positive control, respectively. Hydroquinone is a specialized drug used as a melamine inhibitor. In addition, kojic acid is recognized as a whitening effect, it may be used as one of the raw materials of the cosmetic composition. However, kojic acid has a strong irritation to the skin, and it has recently been reported that it may cause various cancers. Five days after the extract was treated, 1 N NaOH was treated to dissolve melanin (melanin), and the absorbance was measured at 405 nm using a spectrophotometer.

The measurement results are shown in FIG. 6. 6, it was confirmed that the Astragalus extract according to the present invention has an effect of inhibiting pigmentation in a concentration-dependent manner. At the 5 ppm concentration, the degree of pigmentation was lower than that of the hydroquinone treated group. In particular, at 25 ppm concentration, the degree of pigmentation was lower than that of the control group without treatment of the stimulus. Through this, the Astragalus extract according to the present invention was confirmed that the pigmentation inhibition effect is excellent, and further has a whitening effect.

[ Experimental Example  5] Acne  Scar suppression effect in in vitro  evaluation

In order to evaluate effectively the acne scar suppression effect of Astragalus extract, we used in vitro acne scar model using sebaceous gland cells similar to human acne lesions. 6.0 x 10 ⁴ golden hamster sebaceous gland cells were inoculated into 24 well culture plates. After inoculation, the cells were allowed to adhere to the culture plate bottom for one day. At this time, the medium was fermented with fetal bovine serum (JH Bioscience, Tokyo, Japan) in DMEM / Ham's F12 medium ((1: 1) (DMEM / F12) (Invitrogen, Carlsbad, Calif.)). 10% was added and penicillin 100 mg / ml and streptomycin 100 mg / ml (all from GIBCO, Milan, Italy) were used.

50 days of linoleic acid, 50 μM of arachidonic acid, 10nM of dihydrotestosterone, 0.5% of P. acnes were treated as stimulants for acne-inflammation of cells after one day . . At the same time, the extract was treated to observe the effect of acne scars by irritants. DMSO was used as a negative control, and 100 nM of isotretinoin, which is widely used as an acne treatment professional medicine, was used as a positive control. One day after the stimulus and extracts were treated, the gelatin degradation activity of the matrix metalloproteinase (MMP) dissolved in the culture was measured using gelatin zymography.

More specifically, the following procedure was performed: 10% containing 2 mg / ml gelatin by mixing 5 μl of cell culture and 5 μl of Tris-Glycine sample buffer (Invitrogen, Carlsbad, Calif.) The acrylamide gel was electrophoresed at 150 V for 2 hours. The gel was separated from the mold and allowed to react for 30 minutes in rerening buffer, 30 minutes in developing buffer at room temperature, and then placed in developing buffer for 8 hours at 37 ° C. Reacted for a while. Developing buffer was removed, washed three times with PBS, and stained with SimplyBlue (Invitrogen, Carlsbad, Calif.) For 1 hour. The stained gel was washed with distilled water until the band and background were sufficiently separated and observed.

Experimental results are shown in FIGS. 7 to 9. In Figure 7, it can be seen that the MMP-9 and MMP-2 separated by electrophoresis. In Figure 8 it can be seen that the Astragalus extract of the present invention has an MMP-9 inhibitory effect. In addition, in Figure 9, the Astragalus extract, it can be seen that MMP-2 inhibitory effect is superior to isoteretinoin (isotretinoin) which is widely used as a drug for treating acne.

Examples of the formulation of the composition are described below, but are not intended to limit the present invention is intended to be described in detail only.

Formulation Example 1 Preparation of Soft Capsule

Astragalus extract 80 mg, vitamin E 9 mg, vitamin C 9 mg, palm oil 2 mg, vegetable hardened oil 8 mg, lead 4 mg and lecithin 9 mg were mixed and mixed according to a conventional method to prepare a soft capsule filling solution. 400 mg per capsule was filled to prepare a soft capsule. In addition, a soft capsule sheet was prepared at a ratio of 66 parts by weight of gelatin, 24 parts by weight of glycerine, and 10 parts by weight of sorbitol solution and filled with the filler to prepare a soft capsule containing 400 mg of the composition according to the present invention. .

Formulation Example 2 Preparation of Tablet

Astragalus extract 80 mg, vitamin E 9 mg, vitamin C 9 mg, galactooligosaccharide 200 mg, lactose 60 mg and malt sugar 140 mg are mixed, granulated using a fluidized bed dryer, and then 6 mg of sugar ester is added. It was. Tablets were prepared by compression of 504 mg of these compositions in a conventional manner.

Formulation Example 3 Preparation of Drink

80 mg of Astragalus extract, 9 mg of vitamin E, 9 mg of vitamin C, 10 g of glucose, 0.6 g of citric acid, and 25 g of liquid oligosaccharides were mixed, and 300 ml of purified water was added thereto to fill 200 ml of each bottle. After filling the bottle sterilized for 4 to 5 seconds at 130 ℃ to prepare a beverage.

Formulation Example 4 Preparation of Granules

80 mg of Astragalus extract, 9 mg of vitamin E, 9 mg of vitamin C, 250 mg of anhydrous glucose, and 550 mg of starch were mixed, molded into granules using a fluidized bed granulator, and then filled into fabrics.

Formulation Example 5 Preparation of Soft Cosmetic Water (Skin Lotion)

Purified water 255 mg, Astragalus extract 0.3 mg, Butylene glycol 6.0 mg, Propylene glycol 6.0 mg, Carboxy vinyl polymer 0.3 mg, Fiji-12 nonylphenylether 0.6 mg, Polysorbate 80 1.2 mg, Ethanol 30.0 mg, Triethanolamine 0.3 For each of the mg, and preservatives, colorants, and fragrances in small amounts, according to the conventional method for preparing the flexible softener, the above-mentioned ingredients were added in the indicated amounts and mixed uniformly, thereby preparing the desired softener.

Formulation Example 6 Preparation of Nutrients Longevity (Milk Lotion)

Purified water 234 mg, Astragalus extract 0.3 mg, Beeswax 12.0 mg, Polysorbate 60 4.5 mg, Solbitan sesquioleate 4.5 mg, Liquid paraffin 1.5 mg, Montana 202 (manufactured by Seppic) 15 mg, Glycerin 9.0 mg, Butylene glycol 9.0 mg, propylene glycol 9.0 mg, carboxyvinyl polymer 0.3 mg, triethanolamine 0.6 mg, and small amounts of preservatives, pigments, and flavorings, each of which was added to the indicated amounts according to the conventional method for preparing nutrient cosmetics. After mixing, the desired nutrient cosmetics were prepared.

Formulation Example 7 Preparation of Massage Cream

Purified water 70 mg, Astragalus extract 0.3 mg, Beeswax 30.0 mg, Polysorbate 60 4.5 mg, Fiji 60 Cured castor oil 6.0 mg, Sorbitan sesquioleate 2.4 mg, Liquid paraffin 120.0 mg, Squalane 15.0 mg, Montana 202 (manufacturer (Seppic) 12.0 mg, glycerin 15.0 mg, butylene glycol 12.0 mg, propylene glycol 12.0 mg, triethanolamine 0.6 mg, and for each small amount of preservatives, pigments, flavorings, according to the conventional method for producing a massage cream, After addition to the content shown in the mixture uniformly, the desired massage cream was prepared.

Formulation Example 8 Preparation of Pack

Astragalus extract 0.5 mg, beta-1,3-glucan 1.0 mg, polyvinyl alcohol 13.0 mg, sodium carboxymethylcellulose 0.2 mg, glycerin 5.0 mg, allantoin 0.1 mg, ethanol 6.0 mg, ping-12-12 nonylphenyl ether 0.3 mg, poly Sorbate 60 0.3 mg, and for each of the small amounts of preservatives, pigments, and flavorings, purified water was added, and in accordance with the conventional method of preparing the cream, the above ingredients were added in the amounts shown in the mixture, uniformly mixed, and then the desired pack was added. Prepared.

Formulation Example 9 Preparation of Gel

Astragalus extract 0.05 mg, Beta-1,3-glucan 0.1 mg, ethylenediamine sodium acetate 0.05 mg, glycerin 5.0 mg, carboxyvinyl polymer 0.3 mg, ethanol 5.0 mg, Fiji-60 cured castor oil 0.5 mg, triethanolamine 0.3 mg For each small amount of, and preservatives, pigments, and flavorings, purified water was added, and according to a conventional method for preparing a pack, the above ingredients were added in the amounts indicated and uniformly mixed to prepare a desired pack.

Formulation Example 10 Ointment in External Skin Preparation

Astragalus Extract 2.0 mg, Beta-1,3-Glucan 10.0 mg, Beeswax 10.0 mg, Polysorbate 60 5.0 mg, Fiji 60 Cured Castor Oil 2.0 mg, Sorbitan Sesquioleate 0.5 mg, Vaseline 5.0 mg, Liquid Paraffin 10.0 mg, squalane 5.0 mg, shea butter 3.0 mg, caprylic / capric triglyceride 5.0 mg, glycerin 10 mg, propylene glycol 10.2 mg, triethanolamine 0.2 mg, and purified water is added to each of the small amounts of preservatives, pigments and flavors. In addition, according to the conventional method for preparing an ointment, the above ingredients were added in the amounts shown to uniformly mix, and then the desired ointment was prepared.

 Formulation Example 11 Preparation of Pharmaceutical Agent (Patch) for Local Administration

Astragalus extract 1.0 mg, Beta-1,3-glucan 3.0 mg, hexylene glycol 20.0 mg, diethylamine 0.7 mg, polyacrylic acid (Carbopol 934P) 1.0 mg, sodium sulfite 0.1 mg, polyoxyethylene lauryl ether (EO = 9) For 1.0 mg, polyhydroxyethylenecetylstearyl ether (Cetomacrogol 1000) 1.0 mg, viscous paraffin oil 2.5 mg, caprylic acid ester / capric acid ester 2.5 mg, polyethylene glycol 400 3.0 mg, Purified water was added, and according to a conventional method for preparing a patch, the above components were added in the amounts shown to uniformly mix, and then the desired patch was prepared.

Those skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims.

Figure 1 (GM-CSF), Figure 2 (IL-1 α), Figure 3 (IL-8), and Figure 4 (TNF-α), the inflammatory cytokine of the Astragalus extract according to an embodiment of the present invention Graph showing inhibitory efficacy;

Figure 5 is a graph showing the sebum production inhibitory effect of the Astragalus extract according to an embodiment of the present invention;

Figure 6 is a graph showing the effect of inhibiting acne pigmentation of the Astragalus extract according to an embodiment of the present invention;

7 to 9 is a graph showing the effect of inhibiting acne scars of Astragalus extract according to an embodiment of the present invention.

Claims (8)

A composition for inhibiting acne pigmentation, containing Astragalus extract as an active ingredient. A composition for inhibiting acne scars containing an extract of Astragalus as an active ingredient. The method of claim 2, The Astragalus extract is a composition for inhibiting acne scars, characterized in that to inhibit gelatinase (gelatinase). An external preparation composition for skin, comprising the composition according to claim 1. The method of claim 4, wherein The content of the Astragalus extract, the external composition for skin, characterized in that 0.5 to 20% by weight based on the total weight of the composition. The method of claim 4, wherein The composition for external application for skin, characterized in that the cosmetic formulation. Aftercare composition for acne sequelae containing Astragalus extract as an active ingredient. A food addition or health food composition comprising the composition according to any one of claims 1, 2 or 7.

Images